Mizuho Maintains Outperform on Minimed Group, Raises Price Target to $28
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
Mizuho analyst Anthony Petrone maintains Minimed Group (NASDAQ:MMED) with a Outperform and raises the price target from $26 to $28.
Mizuho analyst Anthony Petrone maintains Minimed Group (NASDAQ:MMED) with a Outperform and raises the price target from $26 to $28.